|
Synonyms: compound C112 [US11453690] | TDI05 | TRD205
Compound class:
Synthetic organic
Comment: Foberigan is the INN for an angiotensin II type 2 (AT2) receptor antagonist that was included in WHO INN Proposed List 135 (July 2026). It is one of the structures claimed in patents held by Beijing Tide Pharmaceutical [2]. The structure of Beijing Tide's lead AT2 antagonist TRD205/TDI05 [1] is identical to that assigned to foberigan.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Mao Q, Zeng Y, Liang H, Hou S, Wang Q, Zhang J, Lan Z, Wang H, Wang J, Zhao H. (2025)
A novel angiotensin II type 2 receptor antagonist TDI05 alleviates the peripheral neuropathic pain. Neurosci Lett, 867: 138369. [PMID:40885515] |
|
2. Zhao Y, Wang H, Wang Y, Li X, Jiang Y, Huang H, Li F, Zhou L, Shao N, Xiao F et al.. (2022)
Receptor inhibitor, pharmaceutical composition comprising same, and use thereof. Patent number: US11453690B2. Assignee: Beijing Tide Pharmaceutical Co Ltd. Priority date: 22/03/2019. Publication date: 27/09/2022. |